Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.69 |
| ▸ | IKZF3 | Q9UKT9 | 8/20 | 0.67 |
| ▸ | TNF | P01375 | 6/20 | 0.67 |
| ▸ | IL1B | P01584 | 4/20 | 0.67 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.67 |
| ▸ | BRD4 | O60885 | 1/20 | 0.67 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.62 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31381350 | 0.96 | CRBN (0.64) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL19436853 | 0.95 | CRBN (0.64) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL21741558 | 0.95 | CRBN (0.62) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL20573654 | 0.95 | CRBN (0.64) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL24745305 | 0.95 | CRBN (0.62) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL19453046 | 0.95 | CRBN (0.65) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL23575626 | 0.95 | CRBN (0.64) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL23575346 | 0.95 | CRBN (0.64) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL24142129 | 0.95 | CRBN (0.64) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL22533228 | 0.95 | CRBN (0.65) | CRBNIKZF3TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025010326-A2 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | CRBN 1/4885IKZF3 327/4885TNF 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.